The rise of injectable peptide hype and the lack of human safety data
A recent investigation reveals that injectable peptides marketed for fitness and anti-aging in Ireland lack clinical evidence and may pose serious health risks.
Injectable peptides are being sold on a grey market in Ireland, touted online for muscle growth, injury recovery and longevity despite never having been approved as medicines. The investigation highlighted popular compounds like BPC-157, TB-500 and MOTS-c, whose purported benefits stem mainly from rodent experiments; human data are limited to small, flawed studies. The Health Products Regulatory Authority cautioned that unregulated use can lead to infection, contamination and dosing mistakes, and warned that immune reactions are poorly understood.
Industry analysts estimate the global peptide market could reach $164 billion by 2026, underscoring the profit motive behind the hype. Experts compare the situation to past health fads that later proved dangerous, concluding that current peptide use is an expensive gamble with uncertain long-term health consequences.
Why it matters
Consumers are spending on unproven peptide injections that may cause serious, unknown health problems.
In this story
